Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kohei Togami has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Sumio Chono

    The Division of Clinical Pharmacy, Graduate School of Pharmaceutical Science, Hokkaido University of Science, 7-Jo 15-4-1 Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan

    22 shared publications
  • Sumio Chono

    Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science

    15 shared publications
  • Kazuhiro Morimoto

    Division of Pharmaceutics, Hokkaido Pharmaceutical University School of Pharmacy, 7-15-4-1 Maeda, Teine, Sapporo, Hokkaido, 006-8590, Japan

    10 shared publications
  • Hitoshi Tada

    Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan

    9 shared publications
  • Hitoshi Tada

    Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 7-Jo 15-4-1 Maeda, Teine, Sapporo, Hokkaido 006-8585, Japan

    8 shared publications
  • Yukimune Kanehira

    Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Hokkaido Pharmaceutical University, 7-Jo 15-4-1 Maeda, Teine, Sapporo, Hokkaido 006-8590, Japan

    7 shared publications

Latest Publications

  • Open Access

    A Compensated Förster Resonance Energy Transfer-Based Platform for Quantitative Assessment of Liposome Integrity in Inhalation Drug Delivery

    by Kohei Togami, Mio Yasuda, Hiroki Miyajima, Koshiro Kawamura, Yuki Nakamura, Kiyomi Ishizawa, Sumio Chono

    The structural integrity of inhalable liposomal carriers is a key determinant of drug release behavior, pulmonary residence time, and therapeutic efficacy. This study aimed to establish a compensated Förster resonance energy transfer (FRET)-based platform for the quantitative assessment of liposome integrity throughout the inhalation delivery process. By compensation for donor fluorescence bleed-through and direct acceptor excitation, the method enables accurate quantification of FRET signals from liposomes co-loaded with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate (DiD, donor)/1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR, acceptor), using both spectrofluorometry and macroscopic imaging. Upon treatment with Triton X-100, decreases in the compensated FRET/donor ratio were detected at lower concentrations than those required to induce measurable changes in membrane anisotropy and within the same concentration range as the onset of encapsulated 6-carboxyfluorescein release. Using this platform, in vitro aerosol characterization with an Andersen cascade impactor enabled simultaneous analysis of aerodynamic particle size distribution and stage-specific liposome integrity. In vivo experiments in mice—including ex vivo lung imaging and bronchoalveolar lavage fluid analysis—revealed a time-dependent decline in liposome integrity during pulmonary residence. This ability to monitor carrier structural stability from initial deposition through residence—an aspect not readily achieved with conventional single-fluorophore labeling—offers significant advantages for formulation development, stabilization strategies, and dosing regimen optimization. The FRET-based platform could, in principle, be adapted for use with other standardized cascade impactors such as the Next Generation Impactor and is expected to be applicable to a wide range of lipid-based or polymeric nanocarriers, including inhalable vaccines and nucleic acid therapeutics.


  • Type IV Collagen-Targeting Nanoparticles for Efficient Delivery to the Renal Interstitium in Fibrotic Kidneys

    by Yuki Nakamura, Kohei Togami, Sumio Chono

    Introduction: Renal fibrosis is widely recognized as the final common pathway in chronic kidney disease (CKD) progression, culminating in end-stage renal failure, and is characterized by excessive extracellular matrix (ECM) accumulation by renal myofibroblasts within the renal interstitium, ultimately leading to functional decline. In this study, to establish an effective drug delivery system targeting fibrotic lesions in the renal interstitium, we developed nanoparticles modified with short-chain peptides that bind type IV collagen (Col IV), a distinct ECM component predominantly remodeled in fibrosis. Methods: Col IV-targeting nanoparticles were intravenously administered to a unilateral ureteral obstruction (UUO) rat model of renal fibrosis. The distribution of these nanoparticles to the renal interstitium was examined via fluorescence-based ex vivo imaging and analysis of frozen kidney tissue sections. Additionally, we assessed cellular uptake in renal fibroblasts (NRK-49F), with or without transforming growth factor-beta 1 (TGF-β1) stimulation, using flow cytometry. Results: Both Col IV-targeting and non-targeting nanoparticles exhibited increased distribution in the fibrotic renal interstitium compared to healthy renal tissue. Moreover, the Col IV-targeting nanoparticles localized more extensively in the fibrotic interstitium than their non-targeting counterparts. In vitro, Col IV-targeting nanoparticles also showed significantly higher accumulation in NRK-49F cells, irrespective of TGF-β1 stimulation, compared to non-targeting nanoparticles. Conclusion: We successfully fabricated and evaluated Col IV-targeting nanoparticles as a potential drug delivery platform. In a UUO-induced renal fibrosis model, these nanoparticles efficiently migrated to the fibrotic renal interstitium, and in vitro experiments using NRK-49F cells demonstrated enhanced uptake by renal fibroblasts and myofibroblasts, central mediators of ECM deposition in fibrotic progression. These findings suggest that Col IV-targeting nanoparticles may serve as an effective drug carrier for delivering antifibrotic therapies, potentially mitigating CKD progression.


  • Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis

    by Kohei Togami, Yukimune Kanehira, Yuki Nakamura, Hirotsugu Ishii, Ryota Abe, Akiyoshi Yamamoto, Kanako Takehara, Mio Yasuda, Hitoshi Tada, Sumio Chono


  • Renal Interstitial Distribution of Full‐Length IgG and Fab Fragments in Unilateral Ureteral Obstruction‐Induced Fibrotic Kidneys

    by Yuki Nakamura, Kohei Togami, Sumio Chono

    Renal fibrosis, a critical contributor to chronic kidney disease, is characterized by interstitial expansion and excessive extracellular matrix accumulation. Due to their specificity, monoclonal antibodies (mAbs) and their fragments are promising candidates for treating renal fibrosis, but their distribution characteristics in fibrotic kidneys, particularly within the renal interstitium, remain unclear. This study investigated the tissue distribution of full‐length IgG and Fab fragments in a unilateral ureteral obstruction (UUO)‐induced renal fibrosis mouse model. Full‐length IgG and Fab fragments were intravenously administered in UUO‐induced renal fibrosis model mice. The concentrations in each organ and plasma were quantified using enzyme‐linked immunoassay. In addition, the localization within the renal interstitium was evaluated by multiple techniques, including intravital and ex vivo confocal imaging under near‐living conditions and the observation of the tissue sections via an in vivo cryotechnique. Both full‐length IgG and Fab fragments showed higher distribution in fibrotic kidneys than in other organs. Specifically, Fab fragments had excellent selective accumulation in the fibrotic kidneys, whereas full‐length IgG had higher absolute distribution due to slower plasma elimination. Imaging assessments revealed that both had widespread localization within the interstitial spaces of the fibrotic kidneys. Due to their superior selectivity for fibrotic kidneys, Fab fragments can be used to target fibrotic lesions. Due to its prolonged distribution, full‐length IgG may offer advantages in sustained therapeutic effects. This study provides foundational insights into the distribution of mAbs and their fragments in fibrotic kidneys and underscores the importance of further pharmacokinetic analyses to refine antibody‐based therapies.

  • Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis

    by Kohei Togami, Yukimune Kanehira, Yuki Yumita, Hiroaki Ozaki, Rui Wang, Hitoshi Tada, Sumio Chono

    Background: A distinctive pathological feature of idiopathic pulmonary fibrosis (IPF) is the aberrant accumulation of extracellular matrix components in the alveoli in abnormal remodeling and reconstruction following scarring of the alveolar structure. The current antifibrotic agents used for IPF therapy frequently result in systemic side effects because these agents are distributed, through the blood, to many different tissues after oral administration. In contrast to oral administration, the intrapulmonary administration of aerosolized drugs is believed to be an efficient method for their direct delivery to the focus sites in the lungs. However, how fibrotic lesions alter the distribution of aerosolized drugs following intrapulmonary administration remains largely unknown. In this study, we evaluate the intrapulmonary distribution characteristics of aerosolized model compounds in mice with bleomycin-induced pulmonary fibrosis through imaging the organs and alveoli. Methods: Aerosolized model compounds were administered to mice with bleomycin-induced pulmonary fibrosis using a Liquid MicroSprayer®. The intrapulmonary distribution characteristics of aerosolized model compounds were evaluated through several imaging techniques, including noninvasive lung imaging using X-ray computed tomography, ex vivo imaging using zoom fluorescence microscopy, frozen tissue section observation, and three-dimensional imaging with tissue-clearing treatment using confocal laser microscopy. Results: In fibrotic lungs, the aerosolized model compounds were heterogeneously distributed. In observations of frozen tissue sections, model compounds were observed only in the fibrotic foci near airless spaces called honeycombs. In three-dimensional imaging of cleared tissue from fibrotic lungs, the area of the model compound in the alveolar space was smaller than in healthy lungs. Conclusion: The intrapulmonary deposition of extracellular matrix associated with pulmonary fibrosis limits the intrapulmonary distribution of aerosolized drugs. The development of delivery systems for antifibrotic agents to improve the distribution characteristics in fibrotic foci is necessary for effective IPF therapy.


  • Development of LOX-1 antibody modified immuno-liposomes as drug carriers to macrophages in atherosclerotic lesions

    by K. Togami, X. Zhan, K. Ishizawa, K. Miyakoshi, A. Miyao, P. Quan, S. Chono

    We developed a drug delivery system for atherosclerotic lesions using immuno-liposomes. We focused on enhancing the delivery efficiency of the liposomes to macrophages in atherosclerotic lesions by antibody modification of lectinlike oxidized low-density lipoproteins (LDL) receptor 1 (LOX-1). The cellular accumulation of the liposomes in foam cells induced by oxidized LDL (oxLDL) in Raw264 mouse macrophages was evaluated. The cellular accumulation of LOX-1 antibody modified liposomes in oxLDL-induced foam cells and untreated Raw264 cells was significantly higher compared with that of unmodified liposomes. The liposomes were also administered intravenously to Apoeshl mice as an atherosclerosis model. Frozen sections were prepared from the mouse aortas and observed by confocal laser microscopy. The distribution of LOX-1 antibody modified liposomes in the atherosclerotic regions of Apoeshl mice was significantly greater compared with that of unmodified liposomes. The results suggest that LOX-1 antibody modified liposomes can target foam cells in atherosclerotic lesions, providing a potential route for delivering various drugs with pharmacological effects or detecting atherosclerotic foci for the diagnosis of atherosclerosis.


  • Open Access

    Development of Visualization and Analysis Methods for Evaluating Intratumoral Nanoparticle Kinetics for Tumor-Targeted Drug Delivery Using Förster Resonance Energy Transfer in Vivo Live Imaging and Tissue-Clearing Techniques

    by Kohei Togami, Kiyomi Ishizawa, Mio Yasuda, Hitoshi Tada, Sumio Chono

    In this study, the imaging methods for evaluating the kinetics of nanoparticles as drug delivery systems in tumor tissues were improved in BxPC3 tumor-bearing mice. First, Förster resonance energy transfer (FRET) live imaging was selected to quantitatively evaluate nanoparticle kinetics in the tumor tissue of mice. Briefly, and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine iodide (as an acceptor)–and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (as a donor)–co-loaded nanoparticles were administered intravenously to the mice, and imaging was performed using a fluorescence in vivo imager. The fluorescence intensities of images were acquired in the FRET, donor, and acceptor channels, and the nanoparticle kinetics in the tumor region was quantified by compensating for bleed-through. Second, in the cleared tumor tissue of mice, the difference in evaluation properties between the two- and three-dimensional visualization of the nanoparticles was examined. In brief, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI)-loaded nanoparticles were intravenously administered to the mice after fluorescently labeled tomato lectin treatment to visualize tumor vessels. Excised tumor tissue was cleared and observed using laser-scanning confocal microscopy, and three-dimensional images were reconstructed. The three-dimensional minimum distances traveled by DiI from the tumor vessels were calculated using information about the two-dimensional distance and the slicing position using the Pythagoras theorem. These imaging techniques should facilitate the development of drug delivery systems for cancer.